Nintedanib to prevent lung inflammation from radiation
Treatments studied
Part of Injuries & trauma, Lungs & breathing clinical trials.
This trial tests a drug called nintedanib to see if it can prevent radiation-related lung inflammation (pneumonia) in people with lung cancer that cannot be surgically removed. It may help protect your lungs during radiation treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that cannot be removed by surgery and is not caused by EGFR or ALK gene changes.
- You have at least one measurable tumor on a CT or MRI scan that is at least 1 cm in size.
- You are in fairly good physical condition (able to do daily activities with limited effort).
- You do not have serious lung conditions like pulmonary fibrosis or active tuberculosis, or a history of major bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether breathing in steroid medicine before and during radiation can lower how often and how badly “radiation lung inflammation” (radiation pneumonitis) happens in people with lung cancer. If you qualify, it may help protect your lungs while you receive radiation with chemotherapy or targeted therapy.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
Hear when a new Radiation Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.